Drugs List

Therapeutic Indications

Uses

Dermatoses
Severe nappy rash

Treatment of dermatoses, including intertrigo, eczema, seborrhoeic dermatitis, hand dermatitis and pruritis ani et vulvae, in which infection with Candida albicans is a factor. Treatment of severe nappy rash in which infection with Candida albicans is a factor.

Contraindications

Acne vulgaris
Perioral dermatitis
Rosacea
Skin infection
Skin ulcer

Precautions and Warnings

Neonates
Occlusive dressings
Breastfeeding
Pregnancy

Exclude bacterial infection before treatment
Exclude fungal infection before treatment
Exclude viral infection before treatment
Avoid application to broken skin
Avoid contact with eyes
Avoid prolonged application to the face
Breastfeeding: Wash product off breasts prior to breastfeeding infant
Occlusion may cause increased absorption
Adrenal suppression can occur in infants even without occlusion
Elderly patients may be more susceptible to local and systemic effects
Potential for withdrawal symptoms
Rebound effect may occur after cessation of treatment
Discontinue if hypersensitivity reactions occur
Avoid long-term use particularly in infants and children
Maximum duration of treatment 7 days in infants
Advise patient residue on clothing/bedding may cause fire hazard
Fire hazard: Keep away from naked flames and potential sources of ignition
Nappy may act as an occlusive dressing

Rarely, severe skin reactions and adverse effects may occur on stopping treatment with topical corticosteroids. Consider the lowest potency required and counsel patient on safe and effective use.

Topical corticosteroids are not recommended for acne vulgaris, may worsen secondary infected lesions, and should not be used indiscriminately in pruritis.

Pregnancy and Lactation

Pregnancy

Use the combination of hydrocortisone with nystatin, dimeticone and benzalkonium chloride with caution during pregnancy.

The manufacturer advises caution if this product is used during pregnancy. Topical administration of corticosteroids to pregnant animals may cause abnormalities of foetal development. At the time of writing there is limited published information regarding the use of this product during pregnancy. Potential risks are unknown. Topical steroids should not be used in large amounts or for prolonged periods during pregnancy.

Lactation

Use hydrocortisone with nystatin, dimeticone and benzalkonium chloride with caution during breastfeeding.

The manufacturer advises caution if this product is used during breastfeeding and that the cream should be wiped off thoroughly before breastfeeding if it has been applied to the breast or nipple areas. Although poorly absorbed, it is unknown if nystatin enters breast milk. Corticosteroids cross the placenta in different degrees and can be distributed in small amounts in breast milk.

Side Effects

Acne
Adrenal suppression
Contact dermatitis
Contact sensitisation
Cushing's syndrome
Exacerbation of acne
Exacerbation of infection
Hypersensitivity reactions
Hypertrichosis
Perioral dermatitis
Purpura
Rosacea
Skin depigmentation
Striae (irreversible)
Subcutaneous atrophy
Telangiectasia
Thinning of skin

Presentation

Topical formulation containing hydrocortisone, nystatin, dimeticone and benzalkonium chloride.

Drugs List

Therapeutic Indications

Uses

Dermatoses
Severe nappy rash

Treatment of dermatoses, including intertrigo, eczema, seborrhoeic dermatitis, hand dermatitis and pruritis ani et vulvae, in which infection with Candida albicans is a factor. Treatment of severe nappy rash in which infection with Candida albicans is a factor.

Dosage

Adults

Children

Contraindications

Acne vulgaris
Perioral dermatitis
Rosacea
Skin infection
Skin ulcer

Precautions and Warnings

Neonates
Occlusive dressings
Breastfeeding
Pregnancy

Exclude bacterial infection before treatment
Exclude fungal infection before treatment
Exclude viral infection before treatment
Avoid application to broken skin
Avoid contact with eyes
Avoid prolonged application to the face
Breastfeeding: Wash product off breasts prior to breastfeeding infant
Occlusion may cause increased absorption
Adrenal suppression can occur in infants even without occlusion
Elderly patients may be more susceptible to local and systemic effects
Potential for withdrawal symptoms
Rebound effect may occur after cessation of treatment
Discontinue if hypersensitivity reactions occur
Avoid long-term use particularly in infants and children
Maximum duration of treatment 7 days in infants
Advise patient residue on clothing/bedding may cause fire hazard
Fire hazard: Keep away from naked flames and potential sources of ignition
Nappy may act as an occlusive dressing

Rarely, severe skin reactions and adverse effects may occur on stopping treatment with topical corticosteroids. Consider the lowest potency required and counsel patient on safe and effective use.

Topical corticosteroids are not recommended for acne vulgaris, may worsen secondary infected lesions, and should not be used indiscriminately in pruritis.

Pregnancy and Lactation

Pregnancy

Use the combination of hydrocortisone with nystatin, dimeticone and benzalkonium chloride with caution during pregnancy.

The manufacturer advises caution if this product is used during pregnancy. Topical administration of corticosteroids to pregnant animals may cause abnormalities of foetal development. At the time of writing there is limited published information regarding the use of this product during pregnancy. Potential risks are unknown. Topical steroids should not be used in large amounts or for prolonged periods during pregnancy.

Lactation

Use hydrocortisone with nystatin, dimeticone and benzalkonium chloride with caution during breastfeeding.

The manufacturer advises caution if this product is used during breastfeeding and that the cream should be wiped off thoroughly before breastfeeding if it has been applied to the breast or nipple areas. Although poorly absorbed, it is unknown if nystatin enters breast milk. Corticosteroids cross the placenta in different degrees and can be distributed in small amounts in breast milk.

Side Effects

Acne
Adrenal suppression
Contact dermatitis
Contact sensitisation
Cushing's syndrome
Exacerbation of acne
Exacerbation of infection
Hypersensitivity reactions
Hypertrichosis
Perioral dermatitis
Purpura
Rosacea
Skin depigmentation
Striae (irreversible)
Subcutaneous atrophy
Telangiectasia
Thinning of skin

Overdosage

It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

The following number will direct the caller to the relevant local centre (0844) 892 0111

Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

Further Information

Last Full Review Date: March 2020

Reference Sources

Summary of Product Characteristics: Timodine Cream. Alliance Pharmaceuticals Limited. Revised November 2021.